FDA asks Abbott for another 30 days for its decision
This article was originally published in Clinica
The FDA has asked for a further 30-day extension to make its decision on whether Abbott's Lake County diagnostics site conforms to the Quality System Regulation. The FDA had already extended its review period by 45 days in March. The company now expects the FDA to give its answer in mid-May.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.